HARVARD BIOSCIENCE INC - 8-K Filing

Harvard Bioscience provides investor update including FY26 revenue guidance of 3-5% growth and details on 'Project Viking' manufacturing consolidation. (Items: 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $HBIO

Read the full article at SEC EDGAR

More Regulatory news